In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Apellis Pharmaceuticals Inc (APLS), with a price target of $40. The company’s shares closed on Friday at $21.17.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.8% and a 45.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Apellis Pharmaceuticals Inc is a Strong Buy with an average price target of $43.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.84 and a one-year low of $11.45. Currently, Apellis Pharmaceuticals Inc has an average volume of 434.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product.
